COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy of the Transform™ Corneal Allograft for Hyperopia Correction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03671096
Recruitment Status : Withdrawn (The sponsor determined at one study (PRO-010) was sufficient)
First Posted : September 14, 2018
Last Update Posted : March 11, 2020
Information provided by (Responsible Party):
Allotex, Inc.

Brief Summary:

The objective of this clinical study is to evaluate the safety and effectiveness of intrastromal implantation of the Allotex TCA for improving distance vision in hyperopic subjects.

The overall objective with respect to visual outcome is to provide improved vision without the requirement of additional visual aids.

Condition or disease Intervention/treatment Phase
Hyperopia Other: Intrastromal TCA Inlay Not Applicable

Detailed Description:

This research provides a method to primarily correct refractive error by implanting a natural tissue graft. The level of correction will range from +1.00 to +6.00D which represents a range of refractive error that is difficult to manage using the same refractive surgical techniques used to correct myopia.

The other objective is to assess graft tolerance and safety so it can be applied to subjects that require other forms of visual correction.

This technique also permits the potential for graft removal if required and the patient should revert back to their previous prescription as no tissue is removed when applying this technique.

Beginning in 1949 with the pioneering work of Jose Barraquer, there has been an interest in using natural corneal tissue to change the refractive properties of the eye. In recent years, non-allogenic, synthetic corneal implants have received marketing approval in the United Stated and Europe for refractive purposes. Although synthetic implants are made of biocompatible materials they are not equivalent to an allogenic implant in terms of biocompatibility. The Allotex TCA is a piece of acellular cornea, sterilized with electron beam radiation and shaped to a particular shape using a laser. The availability of precise laser shaping systems and sterile corneas are the key factors that make the use of allogenic implants possible.

The implant is placed on the posterior surface of Bowmans layer of the cornea, in a corneal flap formed by a femtosecond laser.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Multi Center Clinical Study to Evaluate the Safety And Effectiveness of the Transform™ Corneal Allograft (TCA) for Treatment of Hyperopia
Estimated Study Start Date : October 2018
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : January 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Intrastromal TCA Inlay
Implant Intrastromal TCA using femto-second laser surgery It is expected to be carried out once only during the study duration
Other: Intrastromal TCA Inlay
An intrastromal inlay that will be provided to correct the required hyperopic correction

Primary Outcome Measures :
  1. Assessment of the accuracy and stability of hyperopia refractive correction following intervention with the Transform™ Corneal Allograft inlay. [ Time Frame: 6 months ]
    The primary effectiveness endpoint is predictability of the refractive error within ±1.00 D of the intended refractive outcome at 6 months post-operatively. A minimum of 65% of eyes should have an achieved manifest refraction within ±1.00 D of the intended refractive outcome.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects must have signed the written informed consent form and been given a copy.
  • 21 years of age or older on the day the surgery is performed.
  • Best distance corrected visual acuity of 20/20 or better in both eyes.
  • Near visual acuity correctable to at least 20/20 in both eyes.
  • Manifest refraction spherical equivalent (MRSE) between +1.00 and +6.00 D with no more than 0.75 D of refractive cylinder in both eyes.
  • Stable vision, i.e. MSRE within 0.50 D over prior 12 months in both eyes.
  • Contact lens wearers must discontinue hard or rigid gas permeable lenses for at least 2 weeks and discontinue soft lenses for at least 3 days prior to baseline examination in both eyes.
  • Contact lens wearers must have two (2) central keratometry readings with regular mires and two (2) manifest refractions taken at least one week apart, with no contact lens wear between. Keratometric values must not differ by more than ±0.50 D in any meridian and MRSE values must not differ more than ±0.50 D in both eyes.
  • Average corneal power of ≥ 41.00 D and ≤ 47.00 D in both eyes.
  • Anticipated postoperative average corneal power (preoperative average corneal power + intended correction) ≤ 50.00 D in both eyes.
  • Subjects must be willing and able to return for scheduled follow-up examinations for 24 months after surgery of the fellow eye.

Exclusion Criteria:

  • Difference of > 0.75 D between the manifest refraction spherical equivalent and the cycloplegic refraction spherical equivalent in either eye.
  • Anterior segment pathology in either eye.
  • Signs or symptoms of clinically significant cataracts in either eye.
  • Residual, recurrent, active ocular or uncontrolled eyelid disease, or any corneal abnormality (including endothelial dystrophy, recurrent corneal erosion, etc.) in either eye.
  • Central corneal thickness <470 microns in either eye.
  • Residual stromal thickness of <300 microns in either eye.
  • Topographic signs of keratoconus (or keratoconus suspect) or other ectatic disorders in either eye.
  • Subjects with clinically significant dry eyes, as determined by Tear Breakup Time (TBUT) of < 7 seconds or the presence of greater than mild symptoms of dryness or discomfort or SPK greater than grade 1.
  • Distorted or unclear corneal mires on topography maps of either eye.
  • Macular degeneration, retinal detachment, or any other fundus pathology that would prevent an acceptable visual outcome in either eye.
  • Any prior ocular surgery in either eye.
  • History of herpes zoster or herpes simplex keratitis in either eye.
  • History of steroid-responsive rise in intraocular pressure (IOP), preoperative IOP >21 mm Hg, glaucoma, or are a glaucoma suspect in either eye.
  • Using systemic medications with significant ocular side effects.
  • Pregnant, lactating, or planning to become pregnant during the course of the study.
  • Known sensitivity to planned study concomitant medications.
  • Participating in any ophthalmic drug or device clinical trial during the time of this clinical investigation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03671096

Layout table for location information
Gemini Augenlaser Wien
Vienna, Opernring 1, Austria, 1010
Sekhraft Augenzentrum Wien
Vienna, Austria, 1010
Medipolis Wilrijk
Antwerp, Boomsesteenweg 223, Belgium, B-2610
Hospital Pierre Paul Riquet
Toulouse, Purpan, France, 31300
Institute Laser Vision Noemie de Rothschild, Fondation Ophthalmolique Adolphe de Rothschild
Paris, France, 75019
Wellington Eye Clinic
Dublin, Beacon Court Sandyford, Ireland, 18
Laser Vista
Basel, Switzerland, 4051
Eye Clinic Orasis AG
Reinach AG, Switzerland, 5734
United Kingdom
Optegra Eye Hospital
London, Marylebone, United Kingdom, W1G 9HT
Corneo Plastic Unit and Eye Bank Queen Victoria Hospital
East Grinstead, United Kingdom, RH19 3DZ
Centre for Sight
London, United Kingdom, W1G 8HZ
Sponsors and Collaborators
Allotex, Inc.
Layout table for investigator information
Study Director: Stephen Slade, MD Study Medical Monitor/Consultant
Layout table for additonal information
Responsible Party: Allotex, Inc. Identifier: NCT03671096    
Other Study ID Numbers: PRO_012
First Posted: September 14, 2018    Key Record Dates
Last Update Posted: March 11, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Allotex, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Refractive Errors
Eye Diseases